PTC reports ~$710M FY2022 total revenue (+30% YoY); guides FY2023 to $940M-$1B

PTC THERAPEUTICS, INC.

2022-FY EPS reported -$7.79 revenue$698,801,000

FY2022 unaudited total revenue ~$710M; DMD franchise net product revenue $507M (Translarna $289M, Emflaza $218M).
Evrysdi collaboration/royalty revenue ~$175M in 2022.
FY2023 total revenue guidance $940M-$1B; DMD franchise net product revenue $545-$565M.
Non-GAAP R&D and SG&A expense guided to $890-$940M; up to $80M milestone payments.
Three registration-directed trial results expected in 2023: sepiapterin (PKU), vatiquinone (MDAS, FA); Upstaza BLA submission H1 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PTC THERAPEUTICS, INC. reported fiscal year ending December 31, 2022 results: revenue total unaudited net revenue of approximately $710 million. Guidance initiated.

Period: fiscal year ending December 31, 2022
Revenue: total unaudited net revenue of approximately $710 million
Guidance: initiated
Result: preliminary results

Exact text from the filing

On January 9, 2023, PTC Therapeutics, Inc. (the “Company”) issued a press release (the “press release”) announcing certain preliminary (unaudited) financial information for its fiscal year ending December 31, 2022, including that the Company expects to report (i) total unaudited net revenue of approximately $710 million

View on SEC.gov

Browse all earnings releases →

PTC THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001070081-23-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.